CY1120290T1 - Ενδοφλεβια παρασκευασματα συνενζυμου q-10 (coq10) και μεθοδοι χρησης αυτων - Google Patents

Ενδοφλεβια παρασκευασματα συνενζυμου q-10 (coq10) και μεθοδοι χρησης αυτων

Info

Publication number
CY1120290T1
CY1120290T1 CY20181100357T CY181100357T CY1120290T1 CY 1120290 T1 CY1120290 T1 CY 1120290T1 CY 20181100357 T CY20181100357 T CY 20181100357T CY 181100357 T CY181100357 T CY 181100357T CY 1120290 T1 CY1120290 T1 CY 1120290T1
Authority
CY
Cyprus
Prior art keywords
hydrophobic active
agent
active agent
water
methods
Prior art date
Application number
CY20181100357T
Other languages
English (en)
Inventor
Niven Rajin Narain
John Patrick Mccook
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44564137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120290(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Berg Llc filed Critical Berg Llc
Publication of CY1120290T1 publication Critical patent/CY1120290T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Αποκαλύπτονται εδώ παρασκευάσματα για παρεντερική χορήγηση συγκεκριμένων υδρόφοβων δραστικών παραγόντων όπως Συνένζυμο Q10. Δίδονται επίσης εδώ μέθοδοι παρασκευής των ιδίων και μέθοδοι αγωγής ογκολογικών διαταραχών με τη χρήση των ιδίων. Τα παρασκευάσματα περιέχουν ένα υδατικό διάλυμα• έναν υδρόφοβο δραστικό παράγοντα ο οποίος είναι διασπαρμένος για να σχηματίζει μία κολλοειδή νανο-διασπορά σωματιδίων• και τουλάχιστον ένα από έναν παράγοντα σταθεροποίησης διασποράς και έναν παράγοντα μείωσης οψωνινοποίησης, όπου η κολλοειδής νανο-διασπορά του δραστικού παράγοντα είναι διασπαρμένη εντός σωματιδίων νανο-διασποράς τα οποία έχουν ένα μέσο μέγεθος μικρότερο από 200-nm. Μέθοδοι παρασκευής των παρεντερικών παρασκευασμάτων περιλαμβάνουν διασπορά του υδρόφοβου δραστικού παράγοντα δια ομογενοποίησης υψηλής πίεσης δια (1) προσθήκης του υδρόφοβου δραστικού παράγοντα σε λουτρό νερού 65°C και ανάμειξης ώστε να σχηματισθεί ένα μείγμα υδρόφοβου δραστικού παράγοντα/νερού• (2) προσθήκης ενός παράγοντα σταθεροποίησης διασποράς στο μείγμα υδρόφοβου δραστικού παράγοντα /νερού και ανάμειξης σε 65°C ώστε να σχηματισθεί ένα μείγμα υδρόφοβου δραστικού παράγοντα/νερού/παράγοντα σταθεροποίησης• (3) προσθήκης ενός παράγοντα μείωσης της οψωνινοποίησης ώστε να σχηματισθεί ένα μείγμα υδρόφοβου δραστικού παράγοντα/νερού/παράγοντα σταθεροποίησης /παράγοντα μείωσης• (4) αναθέρμανσης ενός Μικρορευστοποιητή σε 65°C• και (5) κατεργασίας δια ανάμειξης του μείγματος υδρόφοβου δραστικού παράγοντα/νερού/παράγοντα σταθεροποίησης/παράγοντα μείωσης εντός του Μικρορευστοποιητή σε 65°C έτσι ώστε να σχηματίζεται μία κολλοειδής νανο-διασπορά του υδρόφοβου δραστικού παράγοντα που έχει ένα μέσο μέγεθος σωματιδίων μικρότερο από 200-nm. Παρέχονται εδώ επίσης μέθοδοι αγωγής ογκολογικών διαταραχών δια χορήγησης παρασκευασμάτων που περιγράφονται εδώ, σε ένα υποκείμενο, έτσι ώστε να διεξάγεται η θεραπευτική αγωγή ή πρόληψη της ογκολογικής διαταραχής.
CY20181100357T 2010-03-12 2018-03-30 Ενδοφλεβια παρασκευασματα συνενζυμου q-10 (coq10) και μεθοδοι χρησης αυτων CY1120290T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31363210P 2010-03-12 2010-03-12
US38510710P 2010-09-21 2010-09-21
PCT/US2011/028042 WO2011112900A2 (en) 2010-03-12 2011-03-11 Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof

Publications (1)

Publication Number Publication Date
CY1120290T1 true CY1120290T1 (el) 2019-07-10

Family

ID=44564137

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100357T CY1120290T1 (el) 2010-03-12 2018-03-30 Ενδοφλεβια παρασκευασματα συνενζυμου q-10 (coq10) και μεθοδοι χρησης αυτων

Country Status (26)

Country Link
US (2) US11400058B2 (el)
EP (2) EP2544663B1 (el)
JP (4) JP5968231B2 (el)
KR (2) KR102008658B1 (el)
CN (2) CN105168135A (el)
AU (4) AU2011224207B2 (el)
BR (1) BR112012022916B1 (el)
CA (2) CA3022054A1 (el)
CL (1) CL2012002507A1 (el)
CO (1) CO6620033A2 (el)
CR (1) CR20120507A (el)
CY (1) CY1120290T1 (el)
DK (1) DK2544663T3 (el)
EA (1) EA032941B1 (el)
ES (1) ES2664793T3 (el)
HK (1) HK1219055A1 (el)
IL (1) IL221675B (el)
MX (1) MX344078B (el)
MY (1) MY163995A (el)
NZ (3) NZ701451A (el)
PE (1) PE20130045A1 (el)
PL (1) PL2544663T3 (el)
PT (1) PT2544663T (el)
SG (3) SG10202010355PA (el)
TW (2) TWI602562B (el)
WO (1) WO2011112900A2 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132502A2 (en) 2009-05-11 2010-11-18 Cytotech Labs, Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
WO2011112900A2 (en) 2010-03-12 2011-09-15 Cytotech Labs, Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
AU2012240222B2 (en) 2011-04-04 2017-04-27 Berg Llc Methods of treating central nervous system tumors
EA201490047A1 (ru) 2011-06-17 2014-08-29 Берг Ллк Ингаляционные фармацевтические композиции
KR20200118233A (ko) 2012-06-01 2020-10-14 버그 엘엘씨 조효소 q10을 이용한 고형 종양의 치료
US10933032B2 (en) * 2013-04-08 2021-03-02 Berg Llc Methods for the treatment of cancer using coenzyme Q10 combination therapies
EP3730131A1 (en) * 2013-09-04 2020-10-28 Berg LLC Methods of treatment of cancer by continuous infusion of coenzyme q10
US11458096B2 (en) * 2014-04-09 2022-10-04 Pulse Pharmaceuticals Pvt. Ltd. Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base
AU2016204933B2 (en) * 2015-07-14 2020-02-27 Best Pet Rx Ip, Inc. Poloxamer-based intralesional injections for the delivery of chemotherapeutic agents
US20170189350A1 (en) * 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
CA3063916A1 (en) 2017-05-17 2018-11-22 Berg Llc Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa
JP2021521141A (ja) * 2018-04-09 2021-08-26 オージェネシス インコーポレイテッド バイオキソーム粒子、レドキソーム、それらの作製方法、及びそれらを含む組成物
WO2020081601A1 (en) * 2018-10-15 2020-04-23 Berg Llc Methods of treating pancreatic cancer using coenzyme q10
IL268457B (en) * 2019-08-04 2022-05-01 Omega 3 Galilee Ltd Oil suspension of edible solids and methods of preparation
WO2021102356A1 (en) 2019-11-20 2021-05-27 Berg Llc Combination therapy of a coenzyme q10 compound and radiation therapy for treatment of glioma
WO2023120553A1 (ja) * 2021-12-24 2023-06-29 株式会社カネカ 還元型補酵素ｑ１０の保存方法

Family Cites Families (349)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525350A (en) * 1975-02-20 1985-06-25 The New England Institute, Inc. Methods of stimulating host defense system with coenzymes Q4 to Q.sub.1
JPS5612309A (en) 1979-07-11 1981-02-06 Kyowa Hakko Kogyo Co Ltd Oral drug containing ubidecarenone
JPS5618914A (en) 1979-07-25 1981-02-23 Eisai Co Ltd Ubidecarenone composition having good absorbability
JPS56109590A (en) 1980-02-05 1981-08-31 Zeria Shinyaku Kogyo Kk Production of clathrate compound of coenzyme q10
JPS588010A (ja) 1981-07-08 1983-01-18 Eisai Co Ltd ユビデカレノン含有リポソ−ム
IT1157269B (it) * 1982-03-19 1987-02-11 Seuref Ag Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica
JPS58201711A (ja) 1982-05-19 1983-11-24 Eisai Co Ltd ユビデカレノン含有リポソ−ム被覆体
JPS59148718A (ja) 1983-02-10 1984-08-25 Fujisawa Pharmaceut Co Ltd ユビデカレノン組成物
JPS59148735A (ja) 1983-02-14 1984-08-25 Fujisawa Pharmaceut Co Ltd ユビデカレノン組成物
US4515736A (en) * 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
JPS601124A (ja) 1983-06-16 1985-01-07 Eisai Co Ltd ユビデカレノン含有リポソ−ム被覆体
US5220042A (en) 1984-01-26 1993-06-15 Otsuka Pharmaceutical Co., Ltd. 1,4-benzoquinone derivatives and benzene derivatives, and process for preparing the same
JPS60199814A (ja) 1984-03-24 1985-10-09 Taisho Pharmaceut Co Ltd ユビデカレノン脂肪乳剤
GB8423436D0 (en) 1984-09-17 1984-10-24 Riker Laboratories Inc Preparation of liposomes
IT1191608B (it) 1985-02-01 1988-03-23 Zambon Spa Composizione farmaceutica e forme farmaceutiche che la contengono
US4824669A (en) 1985-04-11 1989-04-25 Board Of Regents, The University Of Texas System Formulations of coenzyme Q10 for intravenous use
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US5192528A (en) 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
DE3524788A1 (de) 1985-07-11 1987-01-22 Lentia Gmbh Stabile, intravenoes applizierbare, waessrige fettemulsion und ein verfahren zu deren herstellung
JPH0665645B2 (ja) 1985-09-18 1994-08-24 日清製粉株式会社 自己乳化型軟カプセル薬液
JPS62123113A (ja) 1985-11-22 1987-06-04 Green Cross Corp:The ユビデカレノン含有脂肪乳剤
SE8603812D0 (sv) 1986-09-12 1986-09-12 Draco Ab Administration of liposomes to mammals
IT1214540B (it) 1986-10-23 1990-01-18 Vincenzo Zappia Mario De Rosa Formulazioni idrosolubili di ubidecarenoni, procedimento per laloro preparazione e composizioni farmaceutiche che li compongono.
JPS63188623A (ja) 1987-01-31 1988-08-04 Taisho Pharmaceut Co Ltd 吸収改善ユビデカレノン製剤
JPS63313727A (ja) 1987-06-17 1988-12-21 Noriyoshi Saeki 外用治療剤
JP2512310B2 (ja) 1987-06-24 1996-07-03 エーザイ株式会社 被覆脂肪乳剤
US5651991A (en) * 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
GB8811410D0 (en) * 1988-05-13 1988-06-15 Unilever Plc Treatment of skin disorders
US5015483A (en) * 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5962243A (en) * 1990-04-18 1999-10-05 Board Of Regents, The University Of Texas System Methods for the identification of farnesyltransferase inhibitors
JP3008131B2 (ja) * 1990-11-14 2000-02-14 ロレアル グリセリンから誘導される非イオン両親媒性化合物、その調製方法、相応する中間体化合物及び前記化合物を含有する組成物
US5298246A (en) 1991-01-09 1994-03-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Stable pharmaceutical composition and method for its production
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
IT1250672B (it) 1991-07-11 1995-04-21 Idb Holding Spa Formulazioni orali di ubidecarenone in soluzione acquosa
US5378461A (en) * 1991-07-12 1995-01-03 Neigut; Stanley J. Composition for the topical treatment of skin damage
US6461593B1 (en) * 1992-02-19 2002-10-08 Biomedical And Clinical Research Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease
EP0627921B1 (en) 1992-02-24 2000-05-31 East Carolina University Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof
IT1256386B (it) * 1992-11-13 1995-12-04 Luigi Boltri Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo
US5602184A (en) * 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
US5885486A (en) 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
DE59406065D1 (de) * 1993-03-24 1998-07-02 Ciba Geigy Ag Verfahren zur Herstellung einer Liposomendispersion im Hochdruckbereich
CA2120197A1 (en) * 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
US5994314A (en) * 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
DE4327063A1 (de) * 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
DE4410238A1 (de) * 1994-03-25 1995-09-28 Beiersdorf Ag Hautpflegemittel
US20020049422A1 (en) * 1994-03-31 2002-04-25 Brewitt Barbara A. Homeopathic preparations
AU692547B2 (en) * 1994-05-06 1998-06-11 Beckman Instruments, Inc. Liquid stable thiol activator
EP0796108A2 (en) 1994-12-06 1997-09-24 Ryan Pharmaceuticals, Inc. Water soluble ubiquinone compositions, prodrugs, and methods relating thereto
US6005086A (en) * 1995-01-13 1999-12-21 The Salk Institute For Biological Studies Farnesoid activated receptor polypeptides, and nucleic acid encoding the same
US5539021A (en) 1995-06-05 1996-07-23 The Dow Chemical Company Process for preparing high internal phase ratio emulsions and latexes derived thereof
US5738868A (en) * 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
DE19537027A1 (de) * 1995-10-05 1997-04-10 Beiersdorf Ag Hautpflegemittel für alte Haut
JP2000502087A (ja) 1995-12-15 2000-02-22 ナショナル リサーチ カウンシル オブ カナダ アジュバンドおよび送達賦形剤としての、アーケオソーム類、補酵素ｑ▲下１０▼を含有するアーケオソーム類、および補酵素ｑ▲下１０▼を含有する他の種類のリポソーム類
US5944012A (en) * 1996-03-25 1999-08-31 Pera; Ivo E. Method for dispensing antioxidant vitamins by inhalation background of the invention
DE19615577A1 (de) * 1996-04-19 1997-10-23 Beiersdorf Ag Verwendung von Salicin als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
TW497974B (en) 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
DE19647352C2 (de) * 1996-11-15 2000-06-29 Aqua Nova Getraenketechnologie Nicht alkoholisches Getränk mit einem Gehalt an Q 10
GB9625895D0 (en) * 1996-12-13 1997-01-29 Riley Patrick A Novel compound useful as therapeutic agents and assay reagents
ES2159938T3 (es) * 1997-02-11 2001-10-16 Mse Pharmazeutika Gmbh Preparados transdermicos, orales e intravenosos de 2,3-dimetoxi-5-metil-6-decaprenil-1,4-benzoquinona.
US20040228910A1 (en) 1997-02-11 2004-11-18 Mse Pharmazeutika Gmbh Transdermal, oral and intravenous formulations of 2, 3-dimethoxy-5-methyl-6-decaprenyl-1, 4-benzoquinone
EP1007018B1 (de) * 1997-02-12 2003-10-08 MSE Pharmazeutika GmbH Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon inder behandlung von tinnitus
AU733692B2 (en) * 1997-02-28 2001-05-24 Regents Of The University Of California, The Inhibition of cell-cell binding by lipid assemblies
US6372234B1 (en) * 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6599513B2 (en) * 1997-05-27 2003-07-29 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US5900230A (en) * 1997-08-18 1999-05-04 Squigle, Inc. Dental products to treat and prevent periodontal disease
WO1999011242A1 (en) * 1997-09-04 1999-03-11 Biozone Laboratories, Inc. Oral liposomal delivery system
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US7348025B2 (en) 1997-09-23 2008-03-25 Research Development Foundation Small particle liposome aerosols for delivery of anticancer drugs
JP4738592B2 (ja) 1997-10-31 2011-08-03 アーチ・デヴェロップメント・コーポレイション ５α−還元酵素活性を調節するための方法及び組成物
US6696484B2 (en) * 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6372880B1 (en) * 1997-12-25 2002-04-16 Mitsui Chemicals, Inc. Copolymer and process for preparing the same
CA2736981A1 (en) 1998-04-14 1999-10-21 Kyowa Hakko Bio Co., Ltd. Process for producing isoprenoid compounds by microorganisms
US6503523B2 (en) * 1998-05-07 2003-01-07 Gs Development A.B. Skin care agents containing combinations of active agents consisting of vitamin a derivatives and UBI- or plastoquinones
US6054261A (en) * 1998-05-20 2000-04-25 Q-Pharma, Inc. Coenzyme Q10 compositions for organ protection during perfusion
AU755993C (en) 1998-06-19 2003-10-30 Skyepharma Canada Inc. Processes to generate submicron particles of water-insoluble compounds
DE19828081C2 (de) * 1998-06-24 2000-08-10 Cognis Deutschland Gmbh W/O-Emulsionsgrundlagen
AU4908699A (en) * 1998-07-16 2000-02-07 Cognis Deutschland Gmbh Use of pit emulsions
US6048886A (en) * 1998-10-05 2000-04-11 Neigut; Stanley Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
IT1304406B1 (it) * 1998-10-21 2001-03-19 Danital Italia S R L Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6200550B1 (en) * 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
CA2260397A1 (en) 1999-01-29 2000-07-29 Atlantis Marine Inc. Method of converting rendered triglyceride oil from marine sources into bland, stable food oil
US20040034107A1 (en) 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20020048551A1 (en) 1999-04-06 2002-04-25 Keller Brian C. Delivery of biologically active material in a liposomal formulation for administration into the mouth
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
US6803193B1 (en) 1999-06-23 2004-10-12 The Penn State Research Foundation Methods to identify modulators of the mevalonate pathway in sterol synthesis
DE59912559D1 (de) 1999-07-02 2005-10-20 Cognis Ip Man Gmbh Mikrokapseln - III
US6334999B1 (en) * 1999-08-27 2002-01-01 Research Development Foundation Liposomal aerosols for delivery of chemotherapeutic retinoids to the lungs
US6656928B1 (en) * 1999-09-02 2003-12-02 Mccadden Michael E. Composition for the topical treatment of rashes, dermatoses and lesions
US6479058B1 (en) * 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
US6630160B1 (en) * 1999-09-07 2003-10-07 Genetic Services Management, Inc. Process to modulate disease risk with doses of a nutraceutical
US20030104080A1 (en) * 1999-09-07 2003-06-05 Singh Parashu Ram Topical urea composition
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7250174B2 (en) 1999-12-07 2007-07-31 Schott Ag Cosmetic, personal care, cleaning agent, and nutritional supplement compositions and methods of making and using same
DE19959546A1 (de) 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
US7083780B2 (en) 1999-12-11 2006-08-01 Cognis Deutschland Gmbh & Co. Kg Cosmetic composition containing hydroxyethers
WO2001045661A2 (de) * 1999-12-20 2001-06-28 Cognis France, S.A. Kosmetische und/oder pharmazeutische zubereitungen
US8753675B1 (en) 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
US6740338B1 (en) 2000-01-20 2004-05-25 Raj K. Chopra Reduced form of Cenzyme Q in high bioavailability stable oral dosage form
US20020044913A1 (en) * 2000-02-11 2002-04-18 Hamilton Nathan D. Cosmetics to support skin metabolism
FR2804864B1 (fr) * 2000-02-11 2003-04-04 Serobiologiques Lab Sa Extraits de residus issus de la fabrication du vin et leur utilisation en cosmetique ou pharmacologie
DE10007322A1 (de) * 2000-02-17 2001-08-23 Cognis Deutschland Gmbh Perlglanzmittel
EP1127567B1 (de) * 2000-02-17 2010-09-01 Basf Se Wässrige Dispersion wasserunlöslicher organischer UV-Filtersubstanzen
FR2805464B1 (fr) 2000-02-25 2003-02-14 Serobiologiques Lab Sa Preparations cosmetiques contenant des extraits de la plante mourera fluviatilis
DE10009996B4 (de) * 2000-03-02 2005-10-13 Cognis Ip Management Gmbh Feststoffgranulate mit monodisperser Korngrößenverteilung, ein Verfahren zu ihrer Herstellung sowie ihre Verwendung
US6447760B2 (en) * 2000-05-08 2002-09-10 Playtex Products, Inc. Sunless tanning compositions
US6468552B1 (en) * 2000-06-02 2002-10-22 Neutrogena Corporation Stabilized compositions containing oxygen-labile active agents
DE10031703A1 (de) 2000-06-29 2002-01-10 Beiersdorf Ag Verwendung von Calcium freisetzenden oder bindenden Substanzen zur gezielten Schächung oder Stärkung der Barrierefunktion der Haut
EP1170015A1 (de) 2000-07-06 2002-01-09 Laboratoires Serobiologiques(Societe Anonyme) Verwendung von Extrakten des Pilzes Grifola frondosa
DE10033022A1 (de) 2000-07-07 2002-01-17 Cognis Deutschland Gmbh Aerosole
DE10034619A1 (de) 2000-07-17 2002-01-31 Cognis Deutschland Gmbh Aniontensidfreie niedrigviskose Trübungsmittel
DE10036655A1 (de) * 2000-07-26 2002-02-07 Basf Ag Kosmetische oder dermatologische Zubereitungen zur Vermeidung von Hautschädigungen durch Peroxide
DE10036799A1 (de) 2000-07-28 2002-02-07 Beiersdorf Ag Neues Mittel zur Behandlung der Haare und der Kopfhaut
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
FR2813195B1 (fr) 2000-08-29 2003-04-04 Serobiologiques Lab Sa Utilisation d'extraits de la plante cassia alata dans des produits de soin
US6441050B1 (en) * 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
DE10048260A1 (de) * 2000-09-29 2002-04-11 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Aminoguanidin und/oder dessen Derivaten und Strukturanaloga zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
DE10053328A1 (de) 2000-10-27 2002-05-08 Cognis Deutschland Gmbh Kosmetische Zubereitungen
US6756062B2 (en) 2000-11-03 2004-06-29 Board Of Regents University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US6403116B1 (en) * 2000-11-03 2002-06-11 Triarco Inductries, Inc. Coenzyme Q10 formulation
US20070003536A1 (en) 2000-11-21 2007-01-04 Zimmerman Amy C Topical skin compositions, their preparation, and their use
DE10064818A1 (de) * 2000-12-22 2002-06-27 Basf Ag Verwendung von Chroman-Derivaten in kosmetischen oder dermatologischen Zubreitungen
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US6806069B2 (en) 2001-01-09 2004-10-19 Pharmachem Laboratories, Inc. Ubiquinone composition and methods related thereto
FR2819414A1 (fr) 2001-01-15 2002-07-19 Cognis France Sa Preparations cosmetiques et/ou pharmaceutiques comprenant des extraits de plantes dites a resurrection
NL1017205C2 (nl) 2001-01-26 2002-07-29 Adriaan Emanuel Hendricus Wiel Medicinale en cosmetische toepassing van hop en co-enzym Q10.
AU2002243760A1 (en) 2001-01-30 2002-08-12 Board Of Regents University Of Texas System Process for production of nanoparticles and microparticles by spray freezing into liquid
ES2324400T3 (es) 2001-02-11 2009-08-06 Aquanova Ag Procedimiento para la produccion de un concentrado de isoflavonas.
US6300377B1 (en) * 2001-02-22 2001-10-09 Raj K. Chopra Coenzyme Q products exhibiting high dissolution qualities
DE10113046A1 (de) 2001-03-15 2002-09-26 Beiersdorf Ag Selbstschäumende schaumförmige Zubereitungen mit organischen Hydrokolliden und partikulären hydrophobisierten und/oder ölabsorbierenden Festkörpersubstanzen
DE10113053A1 (de) 2001-03-15 2002-09-19 Beiersdorf Ag Selbstschäumende oder schaumförmige Zubereitungen mit anorganischen Gelbildnern und organischen Hydrololloiden
DE10113050A1 (de) 2001-03-15 2002-09-19 Beiersdorf Ag Selbstschäumende oder schaumförmige Zubereitungen organischen Hydrokolloiden
ATE327006T1 (de) 2001-03-23 2006-06-15 Oreal Hautbehandlungsmittel enthaltend fasern und ubichinone
US20030031688A1 (en) * 2001-04-02 2003-02-13 Dipak Ghosh Cosmetic composition with improved skin moisturizing properties
US6727234B2 (en) 2001-04-03 2004-04-27 University Of Iowa Research Foundation Isoprenoid analog compounds and methods of making and use thereof
DE10118269A1 (de) 2001-04-12 2002-10-17 Cognis Deutschland Gmbh Kosmetische Zubereitungen
US6686485B2 (en) 2001-04-19 2004-02-03 Daniel David West Synthesis of coenzyme Q10, ubiquinone
US6582723B2 (en) * 2001-05-03 2003-06-24 Wayne F. Gorsek Cancer immune composition for prevention and treatment of individuals
JP3742602B2 (ja) 2001-05-09 2006-02-08 株式会社カネカ 還元型補酵素ｑの安定な溶液
GB0111279D0 (en) * 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
JP4603192B2 (ja) 2001-05-10 2010-12-22 株式会社カネカ 毛髪頭皮用組成物
DE10123771B4 (de) 2001-05-16 2019-01-10 Beiersdorf Ag Verwendung von Elektrolyten zur Stärkung der Barrierefunktion der Haut
AUPR510001A0 (en) 2001-05-18 2001-06-14 Jupitar Pty Ltd Formulation and method
EP1260212A1 (de) 2001-05-21 2002-11-27 Cognis France S.A. Kosmetische Mittel
EP1262167A1 (de) 2001-06-01 2002-12-04 Cognis France S.A. Kosmetische Zubereitungen enthaltend ein Extrakt von keimenden Pflanzen
US7091241B2 (en) 2001-06-01 2006-08-15 Summa Health System Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
US6506915B1 (en) * 2001-06-14 2003-01-14 Daniel David West Synthesis of coenzyme Q10 ubiquinone
FR2826017B1 (fr) 2001-06-15 2004-06-11 Cognis France Sa Melanges de tensioactifs
SE0102380D0 (sv) 2001-07-02 2001-07-02 Macronova Ab Kräm för behandling av åldersförändringar i huden hos människa
DE10133198A1 (de) 2001-07-07 2003-01-23 Beiersdorf Ag Kreatin enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
JP2003020495A (ja) 2001-07-10 2003-01-24 Cognis Japan Ltd 油脂組成物
DE20122900U1 (de) 2001-07-12 2009-12-03 Aquanova Ag Ubichinon Konzentrat
CH695085A5 (de) * 2001-07-13 2005-12-15 Mibelle Ag Cosmetics Formulierungen zur Pflege der Haut nach Laserbehandlungen und/oder chemischen Peelings und Verwendung der Formulierungen.
TWI235146B (en) 2001-07-16 2005-07-01 Kaneka Corp Method of stabilizing reduced coenzyme q10 and method of acidic crystallization
US7758893B2 (en) 2001-07-27 2010-07-20 N.V. Nutricia Enteral compositions for the prevention and/or treatment of sepsis
US20050142665A1 (en) 2003-12-23 2005-06-30 Boehringer Ingelheim International Gmbh Laser diffraction method for particle size distribution measurements in pharmaceutical aerosols
US7414720B2 (en) 2001-07-27 2008-08-19 Herbert Wachtel Measuring particle size distribution in pharmaceutical aerosols
US6699464B1 (en) 2001-07-30 2004-03-02 Stiefel Laboratories, Inc. Compositions for treatment of hyperpigmentation and methods for making and using such compositions
EP1281392A1 (de) 2001-08-02 2003-02-05 Cognis France S.A. Kosmetische und/oder pharmaceutische Zubereitungen enthaltend Pflanzenextrakte
DE10139580A1 (de) 2001-08-10 2003-02-20 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen mit einem Gehalt an Sterinen und/oder C12-C40-Fettsäuren
WO2003032951A1 (en) 2001-08-29 2003-04-24 Dow Global Technologies Inc. A process for preparing crystalline drug particles by means of precipitation
DE10143963A1 (de) 2001-09-07 2003-03-27 Basf Ag Kosmetische und dermatologische Zubereitungen in Form von W/O-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon
DE10143964A1 (de) 2001-09-07 2003-03-27 Basf Ag Emulgatorarme oder emulgatorfreie Systeme vom Typ Öl-in-Wasser mit einem Gehalt an Stabilisatoren und einem aminosubstituierten Hydroxybenzophenon
DE10143962A1 (de) 2001-09-07 2003-03-27 Basf Ag Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon
AU2002339555B2 (en) 2001-09-18 2007-03-01 Ciba Specialty Chemicals Holding Inc. Use of guaiol for treating the skin
DE10150725A1 (de) 2001-10-13 2003-04-17 Cognis Deutschland Gmbh Aniontensidfreie niedrigviskose Trübungsmittel
US7560123B2 (en) 2004-08-12 2009-07-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
ES2261760T3 (es) 2001-10-26 2006-11-16 Cognis Ip Management Gmbh Solucion impregnante para toallitas cosmeticas.
US6753325B2 (en) 2001-11-06 2004-06-22 The Quigley Corporation Composition and method for prevention, reduction and treatment of radiation dermatitis
US20030105031A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders
DE10155769A1 (de) 2001-11-14 2003-05-22 Cognis Deutschland Gmbh Kosmetische und/oder pharmazeutische Emulsionen
DE10160682A1 (de) 2001-12-11 2003-06-18 Cognis Deutschland Gmbh Emollients und kosmetische Zusammensetzungen
US6652891B2 (en) * 2001-12-12 2003-11-25 Herbasway Laboratories, Llc Co-enzyme Q10 dietary supplement
DE10162351A1 (de) 2001-12-18 2003-07-03 Cognis Deutschland Gmbh Kosmetische und/oder pharmazeutische Emulsionen
DE10162026A1 (de) 2001-12-18 2003-07-03 Cognis Deutschland Gmbh Hochkonzentriert fließfähige Perlglanzkonzentrate
ITRM20010755A1 (it) * 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
US20030129253A1 (en) 2002-01-03 2003-07-10 Milley Christopher J. Stable aqueous suspension
US6696082B2 (en) 2002-01-08 2004-02-24 Mccully Kilmer S. Enhanced liposomal thioretinaco ozonide compositions and liposomal carrier
TW200302056A (en) 2002-01-18 2003-08-01 Kaneka Corp Method for stabilizing reduced coenzyme Q10 and composition therefor
CA2471712A1 (en) 2002-01-18 2003-07-24 Basf Aktiengesellschaft Cosmetic or dermatological preparations for preventing damages to skin caused by peroxides
KR100966482B1 (ko) 2002-01-31 2010-06-30 시바 홀딩 인크 미세안료 혼합물
CA2473228C (en) 2002-02-12 2010-12-14 Dsm Ip Assets B.V. Sunscreen compositions as well as dihydropyridines and dihydropyranes
WO2003068008A1 (en) 2002-02-14 2003-08-21 Dsm Ip Assets B.V. Water-dispersible coenzyme q10 dry powders
EP1340486A1 (de) 2002-03-01 2003-09-03 Cognis France S.A. Verwendung von Zuckerestern
JP2005519129A (ja) * 2002-03-05 2005-06-30 クリーブランド ステート ユニバーシティー エアロゾル薬物送達のための凝集粒子
US20030167556A1 (en) 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
WO2003075900A2 (de) 2002-03-09 2003-09-18 Mse Pharmazeutika Gmbh Verwendung von ubichinonen zur beeinflussung der histaminwirkung zur behandlung von bronchitis, asthma, allergischen krankheiten
DE10254315A1 (de) 2002-03-15 2003-10-02 Cognis Deutschland Gmbh Emollients und kosmetische Zubereitungen
TW200304372A (en) 2002-03-20 2003-10-01 Kanegafuchi Chemical Ind Compositions for diabetes
DE10212528A1 (de) 2002-03-21 2003-10-02 Cognis Deutschland Gmbh Ölphasen für kosmetische Mittel
US7811594B2 (en) 2002-03-28 2010-10-12 Beiersdorf Ag Crosslinked oil droplet-based cosmetic or pharmaceutical emulsions
DE10213957A1 (de) 2002-03-28 2003-10-09 Beiersdorf Ag Vernetzte kosmetische oder pharmazeutische phospholipidhaltige Gele und Emulsionen auf der Basis von ethylenoxidhaltigen oder propylenoxidhaltigen Emulgatoren
WO2003082301A1 (en) 2002-03-29 2003-10-09 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
DE10214983A1 (de) 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
DE10217474A1 (de) 2002-04-19 2003-11-06 Cognis Deutschland Gmbh Sonnenschutzemulsion mit Schaumspender
NZ536796A (en) 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
US20060193905A1 (en) 2002-05-14 2006-08-31 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
EP1509209A1 (en) * 2002-05-23 2005-03-02 UMD, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
DE10223486A1 (de) 2002-05-27 2003-12-11 Beiersdorf Ag Kosmetische und/oder dermatologische Zubereitung mit 2,3-Dibenzylbutyrolactonen
ATE334654T1 (de) 2002-06-03 2006-08-15 Ciba Sc Holding Ag Vor uv-strahlen schützende zusammensetzungen
AU2003238872A1 (en) 2002-06-04 2003-12-19 Avicena Group, Inc. Methods of treating cognitive dysfunction by modulating brain energy metabolism
DE10226018A1 (de) 2002-06-12 2003-12-24 Cognis Deutschland Gmbh Zubereitungen mit konjugiertem Linolalkohol
US7147841B2 (en) 2002-06-17 2006-12-12 Ciba Specialty Chemicals Corporation Formulation of UV absorbers by incorporation in solid lipid nanoparticles
AU2003246592A1 (en) 2002-06-26 2004-01-19 Europroteome Ag Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
US7025955B2 (en) 2002-07-31 2006-04-11 Shaklee Corporation Method for maximizing scalp health and inducing enhanced visual and tactile hair quality
US6953786B2 (en) 2002-10-01 2005-10-11 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
KR100484525B1 (ko) 2002-10-15 2005-04-20 씨제이 주식회사 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
US7241456B2 (en) 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
EP1421929A3 (de) 2002-11-21 2004-11-24 Cognis Deutschland GmbH & Co. KG Emollients und kosmetische Zubereitungen
DE10255195A1 (de) 2002-11-27 2004-06-09 Lipoid Gmbh Micellare wasserlösliche Konzentrate
DE10256881A1 (de) 2002-12-05 2004-06-24 Beiersdorf Ag Neue topische Verwendung von Bis-Arylimidazo[1,2-a]thiolanderivaten
US20040110848A1 (en) 2002-12-10 2004-06-10 Peffley Dennis M Method and kit for treating cancer
US9175906B2 (en) 2003-01-15 2015-11-03 Board Of Regents, The University Of Texas System Drug particles from freezing onto a surface
EP1585493B1 (en) 2003-01-20 2010-09-01 Basf Se Triazine derivatives as uv absorbers
US20060140970A1 (en) 2003-01-23 2006-06-29 Adam Telerman Proteic binding partners of TCTP and methods of modulating tumor reversion or cell apoptosis
US20060073106A1 (en) 2003-02-03 2006-04-06 Dsm Ip Assets B.V. Novel stabilized cinnamic ester sunscreen compositions
US7258876B2 (en) 2003-02-05 2007-08-21 Craig Bozzacco Topical composition for treating infectious conditions of skin and mucosa
CN1208052C (zh) * 2003-03-20 2005-06-29 上海家化联合股份有限公司 一种辅酶q10前体脂质体及其制备方法
WO2004085412A2 (en) 2003-03-24 2004-10-07 Ciba Specialty Chemicals Holding Inc. Symmetrical triazine derivatives
US7438903B2 (en) 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US20110318405A1 (en) 2003-06-25 2011-12-29 Charles Erwin Chemical Combination and Method for Increasing Delivery of Coenzyme Q10
US20060035981A1 (en) 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
US20080069779A1 (en) 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US20050036976A1 (en) 2003-08-12 2005-02-17 Joel Rubin Topical skin care composition
WO2005020940A1 (de) 2003-08-27 2005-03-10 Beiersdorf Ag Kapsel deren kapselhülle bei topischer anwendung nicht mehr gesondert warhnembar ist
US7169385B2 (en) 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
WO2005032278A1 (en) 2003-09-29 2005-04-14 Soft Gel Technologies, Inc. SOLUBILIZED CoQ-10
WO2005030169A1 (en) 2003-10-02 2005-04-07 Sembiosys Genetics Inc. Methods for preparing oil bodies comprising active ingredients
DE10347218A1 (de) 2003-10-10 2005-05-12 Cognis Deutschland Gmbh Sonnenschutzmittel
DE10347940A1 (de) 2003-10-15 2005-05-19 Cognis Deutschland Gmbh & Co. Kg Selbstemulgierende Zubereitungen
JP4732898B2 (ja) 2003-10-31 2011-07-27 株式会社カネカ 還元型補酵素ｑ含有組成物
KR101008741B1 (ko) 2003-11-05 2011-01-14 디에스엠 아이피 어셋츠 비.브이. 폴리실록세인계 자외선 여과기를 함유하는 자외선 여과기의총량이 감소된 광보호 조성물
US20050100537A1 (en) 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
TW200524541A (en) 2003-11-17 2005-08-01 Cargill Inc Lecithin-containing granular compositions and methods of their preparation
DE20320413U1 (de) 2003-11-17 2004-08-26 Beiersdorf Ag Kosmetikum mit empfindlichen Inhaltsstoffen
ES2235642B2 (es) 2003-12-18 2006-03-01 Gat Formulation Gmbh Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos.
KR20170102377A (ko) 2004-01-22 2017-09-08 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
US20050226947A1 (en) 2004-02-04 2005-10-13 Dale Kern Agents for sequestering serum aging factors and uses therefore
JP2007523156A (ja) 2004-02-19 2007-08-16 ケマファー インコーポレイティッド 皮膚状態の処置用の局所製剤
US7780873B2 (en) 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
DE102004014615A1 (de) 2004-03-23 2005-10-13 Beiersdorf Ag Taurinhaltige Zubereitungen zur Verbesserung der Hautbarriere
DE102004020627A1 (de) 2004-03-23 2005-10-13 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen
AU2005236840B9 (en) 2004-04-06 2009-12-10 Basf Aktiengesellschaft Cosmetic formulations comprising ZnO nanoparticles
US20050226858A1 (en) 2004-04-09 2005-10-13 Kaneka Corporation Compositions containing reduced coenzyme Q10 and carotenoid
US7723569B2 (en) 2004-04-30 2010-05-25 National Institute Of Agrobiological Sciences Method for producing ubiquinone-10 in plant
RU2375053C2 (ru) 2004-05-18 2009-12-10 Кемийски Инштитут Новая водорастворимая форма коэнзима q10 в форме комплекса включения с бета-циклодекстрином, способ ее получения и ее применение
JP2008500397A (ja) 2004-05-21 2008-01-10 トランセイブ， インク． 肺疾患及び前肺疾患状態の治療
WO2005115306A2 (de) 2004-05-24 2005-12-08 Basf Aktiengesellschaft Keratin-bindende polypeptide
WO2006009825A1 (en) 2004-06-17 2006-01-26 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
JP4927718B2 (ja) 2004-06-18 2012-05-09 シムライズ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング・ウント・コンパニー・コマンジツト・ゲゼルシヤフト ブラックベリー抽出物
KR20070032795A (ko) 2004-06-21 2007-03-22 허치슨 메디파르마 엔터프라이즈 리미티드 항암 화학요법
ATE551048T1 (de) 2004-06-28 2012-04-15 Dsm Ip Assets Bv Proteinhydrolysate enthaltende kosmetische zusammensetzungen
EP1765463B1 (en) 2004-07-01 2014-07-30 E-L Management Corp. Cosmetic compositions and methods containing a tanning agent and liposome-enscapsulated ursolic acid
JP2006070016A (ja) 2004-08-02 2006-03-16 Kaneka Corp 還元型補酵素ｑを含有する美白用組成物
US20060051462A1 (en) 2004-09-03 2006-03-09 Wang Jimmy X Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients
US7288263B2 (en) 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
DE102004046235A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
WO2006044738A2 (en) 2004-10-18 2006-04-27 Maroon Biotech Corporation Methods and compositions for treatment of free radical injury
AU2005300835B2 (en) 2004-11-02 2011-01-20 Dsm Ip Assets B.V. Additive for UV-sunscreen preparations
GB0424891D0 (en) 2004-11-11 2004-12-15 Boots Co Plc Topical compositions
JP2008520563A (ja) 2004-11-16 2008-06-19 バイオアバイラビリティ，インク． 栄養学的に使用するための高濃度自己マイクロエマルジョン化コエンザイムｑ１０調製物
US20060127384A1 (en) 2004-12-09 2006-06-15 Sergio Capaccioli Coenzyme Q10 as antiapoptotic agent
US20060154993A1 (en) 2004-12-17 2006-07-13 Littarru Gian P Method for treating and preventing male infertility
NO20045674D0 (no) 2004-12-28 2004-12-28 Uni I Oslo Thin films prepared with gas phase deposition technique
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
EP1849481A4 (en) 2005-01-07 2012-11-28 Rohto Pharma COMPOSITION FOR TOPICAL APPLICATION
US20080207560A1 (en) 2005-01-07 2008-08-28 Ayako Harada Composition For External Use
US20060188492A1 (en) 2005-01-13 2006-08-24 Chronorx Llc, An Alaska Limited Liability Company Topical management of ocular and periocular conditions
DE102005007980A1 (de) 2005-02-22 2006-02-23 Clariant Gmbh Kosmetische, pharmazeutische oder dermatologische Zubereitungen enthaltend Copolymerwachse
US20060198830A1 (en) 2005-03-01 2006-09-07 Siddharth Shastri Ubiquinone composition and a container for its convenient transport and storage
US20060251690A1 (en) 2005-04-01 2006-11-09 Zymes, Llc Skin enrichment using CoQ10 as the delivery system
EP1712220A1 (en) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
EP1880020A4 (en) 2005-04-29 2009-05-20 Univ Tennessee Res Foundation ANTIOXIDANTIENT TEST WITH CELLULAR BIOMARKERS AND USES THEREOF
US20060280691A1 (en) 2005-06-13 2006-12-14 University Of Alberta Spray freeze dried liposomal ciprofloxacin powder aerosol drug delivery
EP1893159B1 (en) 2005-06-17 2015-09-30 Vital Health Sciences Pty Ltd. A carrier comprising one or more di- and/or monophosphate derivatives of electron transfer agents
ITPD20050224A1 (it) 2005-07-19 2007-01-20 Actimex Srl Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego
WO2007013556A1 (ja) 2005-07-28 2007-02-01 Kaneka Corporation 癌予防用組成物
US20070053985A1 (en) 2005-08-24 2007-03-08 Kaneka Corporation Coenzyme Q10-containing fine particle with excellent dispersibility
US20070071779A1 (en) 2005-09-26 2007-03-29 Leggit Ingenuity, Llc Compositions for delivering lipophilic agents to the intestinal mucosa and method of making thereof
US20070092469A1 (en) 2005-10-26 2007-04-26 Eric Jacobs Topically applied Glucosamine Sulfate and all its related, precursor, and derivative compounds significantly increases the skin's natural produciton of hyaluronic acid for the rejuvenation of healthier younger-looking skin; while PhosphatidylCholine is required to replace its deficiency caused by topical Dimethylaminoethanol (DMAE)
US8506956B2 (en) 2005-10-31 2013-08-13 Kaneka Corporation Method for stabilizing reduced coenzyme Q10
US9265792B2 (en) 2005-11-16 2016-02-23 Patricia A. Riley Integument cell regeneration formulation
US20070248590A1 (en) 2005-12-02 2007-10-25 Sirtris Pharmaceuticals, Inc. Modulators of CDC2-like kinases (CLKS) and methods of use thereof
EP1957039A2 (en) 2005-12-09 2008-08-20 Drugtech Corporation Intravenous essential fatty acid emulsion
US20070172436A1 (en) 2006-01-23 2007-07-26 Jerry Zhang Nonaqueous ascorbic acid compositions and methods for preparing same
US20070184076A1 (en) 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
US20070184041A1 (en) 2006-02-09 2007-08-09 Burja Adam M Methods and compositions related to production of coenzyme q10
WO2008023264A2 (en) 2006-02-09 2008-02-28 Ocean Nutrition Canada, Ltd. Coenzyme q10 production from marine bacteria
GB0603975D0 (en) 2006-03-01 2006-04-05 Etren Methods and agents for reducing oxidative stress
KR101433962B1 (ko) * 2006-03-10 2014-08-25 라보스위스 아게 물질의 용해, 분산 및 안정을 위한 방법, 상기 방법에 따라제조된 제품 및 상기 제품의 이용
US7335384B2 (en) 2006-03-17 2008-02-26 4K Nutripharma International Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
JPWO2007119578A1 (ja) 2006-03-29 2009-08-27 株式会社カネカ 神経系細胞機能改善剤
US8021659B2 (en) 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
TW200810776A (en) 2006-04-28 2008-03-01 Kaneka Corp Purification method of reduced coenzyme Q10
TW200808344A (en) 2006-04-28 2008-02-16 Kaneka Corp Stabilization method of reduced coenzyme Q10
MX2008013855A (es) 2006-05-02 2009-01-29 Univ Miami Formulaciones de co-enzima topica q10 y tratamiento de dolor, fatiga y heridas.
US20080020022A1 (en) 2006-06-05 2008-01-24 Udell Ronald G Chewable co-enzyme q-10 capsule
US20080254017A1 (en) 2006-06-19 2008-10-16 Bodybio, Inc. Methods and compositions for treating symptomes of diseases related to imbalance of essential fatty acids
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
RU2315593C1 (ru) 2006-08-02 2008-01-27 Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" Липосомальная композиция антиоксидантов для ингаляций при заболеваниях легких и верхних дыхательных путей
US8894993B2 (en) 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
EP1897530A1 (en) 2006-09-08 2008-03-12 DSMIP Assets B.V. Skin care composition
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
WO2008058755A1 (en) 2006-11-17 2008-05-22 Abbott Gmbh & Co. Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
WO2008062559A1 (fr) 2006-11-22 2008-05-29 Asahi Kasei Pharma Corporation Supplément diététique, agent anti-fatigue, activateur d'endurance physique, aliment fonctionnel, ou produit cosmétique
EP1927373B1 (en) 2006-11-30 2012-08-22 PARI Pharma GmbH Inhalation nebulizer
US20080138326A1 (en) 2006-12-06 2008-06-12 Kaneka Corporation Method for cancer treatment, carcinogenesis suppression or mitigation of adverse reactions of anticancer agents
US20100098752A1 (en) 2007-01-18 2010-04-22 Pinsky Mark A Materials and Methods for Delivering Antioxidants into the Skin
BRPI0809164B8 (pt) * 2007-03-22 2023-02-28 Berg Llc Composição para administração tópica e composição farmacêutica compreendendo a referida composição
KR100849537B1 (ko) * 2007-07-04 2008-07-31 유효경 코엔자임 큐텐의 나노에멀젼 조성물
CN101091890A (zh) 2007-07-26 2007-12-26 沈阳药科大学 一种复合型乳化剂及用其制备的乳剂及其制备方法
HUE043897T2 (hu) 2007-09-25 2019-09-30 Solubest Ltd Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra
US8815567B2 (en) 2007-11-30 2014-08-26 E I Du Pont De Nemours And Company Coenzyme Q10 production in a recombinant oleaginous yeast
EP2227085A4 (en) 2007-12-06 2013-10-09 Berg Pharma Llc INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY
US8272253B2 (en) 2008-01-22 2012-09-25 Ct Associates, Inc. Particle concentration measurement technology
KR101003204B1 (ko) 2008-02-14 2010-12-21 메콕스큐어메드 주식회사 약물 전달용 고형 지질 나노입자, 그 제조방법, 및 그나노입자를 포함하는 주사제
US20100080785A1 (en) 2008-04-08 2010-04-01 Zymes, Llc Dried formulations
WO2009126764A1 (en) * 2008-04-11 2009-10-15 Cytotech Labs, Llc Methods and use of inducing apoptosis in cancer cells
CN102131407B (zh) 2008-06-23 2015-01-07 维尔恩公司 含有非极性化合物的组合物
US20100099775A1 (en) 2008-10-17 2010-04-22 Alpharx Inc. Method for ameliorating of post-anesthetic recovery
US20100129431A1 (en) 2008-11-24 2010-05-27 Alpharx Inc. Idebenone composition for the treatment of neurological disorders
US20100215725A1 (en) 2009-02-20 2010-08-26 Joseph Schwarz Pharmaceutical composition containing idebenone for the treatment of liver disorders
KR101066197B1 (ko) 2009-04-06 2011-09-20 한국생명공학연구원 코엔자임 ｑ10 나노입자, 그 제조방법 및 상기 나노입자를 포함하는 조성물
WO2010132502A2 (en) 2009-05-11 2010-11-18 Cytotech Labs, Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
US8408429B2 (en) * 2009-11-11 2013-04-02 The Clorox Company Bottle with integral dip tube
PL2533761T3 (pl) 2010-02-11 2019-09-30 Ablynx N.V. Sposoby i kompozycje do wytwarzania aerozoli
WO2011112900A2 (en) 2010-03-12 2011-09-15 Cytotech Labs, Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
US20120064136A1 (en) 2010-09-10 2012-03-15 Nanobio Corporation Anti-aging and wrinkle treatment methods using nanoemulsion compositions
US10869843B2 (en) 2010-11-23 2020-12-22 Chemi Nutra Method for increasing muscle mass and strength
US20120141446A1 (en) 2010-12-02 2012-06-07 Bhiku Patel Oral Nutritional Supplement Delivery System
TWI425914B (zh) 2011-03-21 2014-02-11 Food Industry Res & Dev Inst 含高濃度奈米／次微米疏水性機能化合物之水相分散液之製備方法
MY159478A (en) 2011-05-23 2017-01-13 Malaysian Palm Oil Board A process for producing nano-capsules and nano-beadlets containing phytonutrients derived from palm oil
EA201490047A1 (ru) 2011-06-17 2014-08-29 Берг Ллк Ингаляционные фармацевтические композиции
JP2015512945A (ja) 2012-04-13 2015-04-30 バナー ファーマキャップス，インコーポレイティド 錠剤と液体または半固体の充填剤とを含む軟質弾性カプセル、ならびにそれらの製造方法
WO2013175266A1 (en) 2012-05-21 2013-11-28 Chemi Nutra Inc. Method for increasing muscle mass and strength
WO2014138922A1 (en) 2013-03-15 2014-09-18 Indanio Bioscience Inc. Uses for idebenone and related benzoouinones in ppar-related diseases and conditions
KR20150062802A (ko) 2013-11-29 2015-06-08 삼성전자주식회사 소수성 활성 성분을 포함하는 내부 리포좀을 포함하는 이중막 리포좀, 및 그의 용도
US20170072069A1 (en) 2014-02-27 2017-03-16 B-Organic Films Corp. Bioactive agents under water dispersible solid forms for food, nutraceutical, agricultural and pharmaceutical applications
CA2945323A1 (en) 2014-04-08 2015-10-15 University Of Massachusetts Food matrices and methods of making and using

Also Published As

Publication number Publication date
JP2016199573A (ja) 2016-12-01
CR20120507A (es) 2012-12-04
TWI602562B (zh) 2017-10-21
BR112012022916A2 (pt) 2016-08-09
CO6620033A2 (es) 2013-02-15
SG10202010355PA (en) 2020-11-27
EA201270735A1 (ru) 2013-02-28
IL221675B (en) 2018-06-28
AU2016200991B2 (en) 2017-12-21
CA2791693A1 (en) 2011-09-15
AU2018202010B2 (en) 2020-02-27
KR101907411B1 (ko) 2018-10-12
EA032941B1 (ru) 2019-08-30
DK2544663T3 (en) 2018-04-16
KR20180112876A (ko) 2018-10-12
CA2791693C (en) 2018-11-27
CN105168135A (zh) 2015-12-23
JP6861682B2 (ja) 2021-04-21
AU2011224207B2 (en) 2015-11-19
PE20130045A1 (es) 2013-01-28
AU2011224207A1 (en) 2012-09-13
KR20140021467A (ko) 2014-02-20
MX344078B (es) 2016-12-05
EP2544663A2 (en) 2013-01-16
NZ720022A (en) 2018-07-27
US20110229554A1 (en) 2011-09-22
JP5968231B2 (ja) 2016-08-10
KR102008658B1 (ko) 2019-08-08
US20230165809A1 (en) 2023-06-01
TW201703761A (zh) 2017-02-01
CN102892412A (zh) 2013-01-23
CA3022054A1 (en) 2011-09-15
MX2012010513A (es) 2013-01-18
EP3366280A1 (en) 2018-08-29
US11400058B2 (en) 2022-08-02
AU2016200991A1 (en) 2016-03-24
WO2011112900A3 (en) 2012-01-12
WO2011112900A2 (en) 2011-09-15
ES2664793T3 (es) 2018-04-23
SG10201501872XA (en) 2015-05-28
EP2544663A4 (en) 2013-10-30
TWI610671B (zh) 2018-01-11
HK1219055A1 (zh) 2017-03-24
PT2544663T (pt) 2018-04-05
TW201141467A (en) 2011-12-01
JP6431003B2 (ja) 2018-11-28
JP2013522233A (ja) 2013-06-13
NZ701451A (en) 2016-09-30
PL2544663T3 (pl) 2018-09-28
JP2019059734A (ja) 2019-04-18
SG183508A1 (en) 2012-10-30
JP2021050221A (ja) 2021-04-01
MY163995A (en) 2017-11-15
NZ602057A (en) 2015-06-26
CL2012002507A1 (es) 2012-12-21
AU2018202010A1 (en) 2018-04-12
AU2020203490A1 (en) 2020-06-18
EP2544663B1 (en) 2018-01-03
BR112012022916B1 (pt) 2021-11-09
CN102892412B (zh) 2015-09-30

Similar Documents

Publication Publication Date Title
CY1120290T1 (el) Ενδοφλεβια παρασκευασματα συνενζυμου q-10 (coq10) και μεθοδοι χρησης αυτων
Huang et al. Tumor‐targeted inhibition of monocarboxylate transporter 1 improves T‐cell immunotherapy of solid tumors
Salazar et al. Combinative particle size reduction technologies for the production of drug nanocrystals
Yang et al. Conferring BiVO4 nanorods with oxygen vacancies to realize enhanced sonodynamic cancer therapy
Yu et al. Targeting autophagy in skin diseases
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
JP2013522233A5 (el)
NZ595372A (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
TN2014000345A1 (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
PH12014502314B1 (en) Optimised subcutaneous therapeutic agents
EA201892797A1 (ru) Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака
AR085527A1 (es) Una composicon farmaceutica para tratar una enfermedad en la cavidad oral que comprende rebamipida
UA101035C2 (ru) Смягчающая композиция на основе вазелина, глицерина и вазелинового масла
EP2726076B1 (en) Combination therapy
TW201622704A (zh) 類胡蘿蔔素的醫藥組合物
Yuan et al. Fabrication of Interface Engineered S‐Scheme Heterojunction Nanocatalyst for Ultrasound‐Triggered Sustainable Cancer Therapy
MX2017009733A (es) Uso de una mezcla de polímeros de glucosa modificados para reducir la metástasis tumoral.
Renukuntla et al. Folate decorated polymeric nanoparticles for enhanced lutein uptake for treatment of age-related macular degeneration
Santos-Neto et al. Chitosan Coated Nanostructured Lipid Carriers Containing Dexamethasone Acetate
Mikhaylov et al. ANTICANCER ACTIVITY OF CRUMPLED ALUMINUM NANOSHEETS THROUGH DISRUPTION OF ION BALANCE IN TUMOR MICROENVIRONMENT
Riley et al. Magnetically Stimulated Release of a Model Drug From a Magnetic Drug Carrier
Kumar et al. Capillary Hemangioma, Is Propranolol The Treatment Of Choice?
Pillers et al. Over-Expression of Dystrophin Isoform Dp71 Does Not Alter the Mouse ERG
Nasrollahi et al. Usage of nanoemulsion in preparation of chemical sunscreen
Manassero et al. Combined Melphalan/Topotecan intra-arterial chemotherapy (MT-IAC) for salvage in retinoblastoma relapse following melphalan intra-arterial chemotherapy (M-IAC)